Financial Performance - Gross originations grew by 25.3% year-over-year in Q3 2025[128] - Revenue increased by 22.8% year-over-year in Q3 2025[128] - Adjusted EBITDA increased to $4.4 million in Q3 2025[23] - Fixed cash operating expenses decreased by 21.4% year-over-year in Q3 2025[128] Marketplace Activity - 61% of Q3 2025 gross originations started in the app marketplace[23] - KPay gross originations grew 66% year-over-year in Q3 2025, representing approximately $26 million and 41% of total gross originations[23] - Total app originations since launch in Q1 2023 reached $339.7 million[37] - Total KPay originations since launch in Q1 2023 reached $196.1 million[38] Customer Base - Repeat customers accounted for 55.3% of Q3 2025 gross originations[16] - Total application volume grew by over 80% year-over-year in Q3 2025[19] Market Opportunity - The company estimates a total US addressable market of $50-60 billion[15]

Financial Highlights - Total revenue & reserve income reached $740 million, a 66% year-over-year increase[11] - Adjusted EBITDA was $166 million, up 78% year-over-year[11] - Adjusted EBITDA margin was 57%, a 737 bps increase year-over-year[11] Stablecoin Network Growth - USDC onchain volume reached $96 trillion, a 68x year-over-year increase[11] - Stablecoins in circulation grew 59% year-over-year[16] - USDC onchain transaction volume increased 74x year-over-year[22] - CCTP volume increased 74x year-over-year[22] - Meaningful wallets increased 77% year-over-year[22] Guidance Update for FY 2025 - Other revenue is expected to be between $90 million and $100 million[52] - Revenue less Distribution Costs (RLDC) Margin is expected to be approximately 38%[52] - Adjusted operating expenses are projected to be between $495 million and $510 million[52]

Financial Performance (Q2 FY26) - Revenue from Operations increased by 48% year-over-year to INR 3,509 million[35] - Gross Margins (Revenue less Service Cost) grew by 34% year-over-year to INR 1,257 million[35] - Adjusted EBITDA surged 216% year-over-year to INR 212 million[35] Financial Performance (H1 FY26) - Revenue from Operations increased by 64% year-over-year to INR 5,607 million[21] - Gross Margins (Revenue less Service Cost) grew by 37% year-over-year to INR 2,413 million[21] - Adjusted EBITDA surged 214% year-over-year to INR 418 million[21] Corporate Client Acquisition - Yatra closed 34 new corporate accounts during the quarter with potential annual billing of INR 2,615 million[35] Corporate Business - Yatra caters to over 1,300 large & medium corporates and approximately 58,000 SME clients, with an addressable employee base of more than 9 Million[12] Consumer Business - Yatra has approximately 156 million registered customers[14] - Total consumer visits are approximately 106 million, a 24% year-over-year increase[14] Scheme of Amalgamation - The Mumbai Bench of the Hon'ble National Company Law Tribunal ('NCLT"), through its final order dated October 14, 2025 has approved and sanctioned the Scheme with the appointed date of the amalgamation being April 01, 2024[52]

Production and Growth - Gold Fields aims to increase production to a sustainable level of 25 Moz to 30 Moz [15] - The company anticipates sector-leading production growth, with an 8% Compound Annual Growth Rate (CAGR) over the next five years [15] - A 6% production CAGR is expected from 2024 to 2030, accompanied by margin expansion [15] - 2025 production guidance is set at 225 Moz to 245 Moz [39] Costs and Investments - All-in Sustaining Cost (AISC) for 2025 is projected to be between US$1,500/oz and US$1,650/oz [39] - All-in Cost (AIC) for 2025 is expected to range from US$1,780/oz to US$1,930/oz [39] - Discretionary capital investment of approximately US$2 billion is planned over five years (2026-2030) [56, 58] - Windfall project is estimated to require US$17 billion to US$19 billion in growth capital [53] Assets and Reserves - Tarkwa's Mineral Reserve estimate as of December 31, 2025, is 74 Moz [8, 188] - St Ives aims to reduce AISC to US$1,500/oz by 2030 and maintain approximately 35 Moz Reserve to sustain production into the 2040s [111] - South Deep's 2024 Mineral Reserves are 31 Moz [175]

Financial Performance Highlights - Third-quarter net sales reached $2.6 billion, a 6% increase year-over-year on a reported basis and a 5% increase in constant currency[16] - Third-quarter core diluted EPS was $0.79[12] - The company's free cash flow for the first nine months of the year was $1.2 billion[15] Segment Performance - Surgical net sales in the third quarter were $1.42 billion, up 6% on a reported basis and 5% in constant currency[23] - Vision Care net sales in the third quarter were $1.169 billion, up 6% on a reported basis and 5% in constant currency[24] - For the first nine months of 2025, Vision Care accounted for 45% ($3.4 billion) and Surgical accounted for 55% ($4.2 billion) of the company's $7.6 billion in sales[22] Profitability Metrics - Third-quarter IFRS operating margin was 12.8%, a decrease of 80 basis points year-over-year[16] - Third-quarter core operating margin was 20.2%, a decrease of 40 basis points year-over-year[14] - For the first nine months of 2025, the IFRS operating margin was 13.7%[32] - For the first nine months of 2025, the core operating margin was 20.0%[45] Outlook - The company maintained its full-year 2025 net sales outlook of $10.3 to $10.4 billion, representing a 4% to 5% increase in constant currency[57] - The company maintained its full-year 2025 core diluted EPS outlook of $3.05 to $3.15, representing a 0% to +2% increase in constant currency[57]

CARVYKTI® Performance and Market Position - CARVYKTI® achieved net trade sales of $524 million in Q3 2025, representing an 84% year-over-year (YoY) growth[23] - Over 9,000 clinical and commercial patients have been treated with CARVYKTI® to date[23] - CARVYKTI® label was updated by the FDA to include Overall Survival (OS) analysis from the Phase 3 CARTITUDE-4 study[23] - U S QoQ growth of 11% primarily driven by continued strong demand with 60% utilization in earlier line settings[51] - OUS QoQ growth of 58% primarily driven by launch uptake in 14 markets worldwide[51] Clinical Advancements and Pipeline - CARTITUDE-4 study showed approximately a 70% reduction in the risk of progression or death in patients who received cilta-cel[27] - The CARTITUDE-4 study also demonstrated a 45% reduction in the risk of death in patients receiving cilta-cel versus standard of care (SOC)[27] - The company has 10 pipeline programs, including hematologic malignancies, solid tumors, and autoimmune diseases[43] - Greatest benefit in 1 prior line of therapy, reducing the risk of progression or death versus SOC with a hazard ratio (HR) of 0 35[36] Financial Performance and Outlook - The company has a cash position of approximately $1 billion as of September 30, 2025[43, 75] - Operating margin improved from -142% in Q2 2023 to -16% in Q3 2025[66] - Adjusted net loss improved from $42 million in Q3 2024 to $19 million in Q3 2025[68]

Q3 - 2 5 Earning s N o vem ber 1 2 , 2 0 2 5 B e n n y E p p s t e i n CEO Had a r R a h a v CFO 1 SAFE HARBOR PROVISION This conference call will contain forward-looking statements. Forward-looking statements in the conference call involve several risks and uncertainties, including, but not limited, to the Company's statements about its commitment to delivering solutions that are transforming the assurance landscape, continued adoption and investment in AI and 5G as well as other favorable market trends, t ...

Financial Performance - GMV reached RMB 727 billion, showing seven consecutive quarters of year-over-year growth[6] - Revenue reached RMB 666 billion, also marking seven consecutive quarters of year-over-year growth[6] - Non-GAAP net profit was RMB 1013 million, achieving twelve consecutive quarters of Non-GAAP profitability with a margin of 15%[6] - GAAP net profit was RMB 829 million, demonstrating seven consecutive quarters of GAAP profitability with a margin of 12%[6] - Gross profit was RMB 19226 million with a gross margin of 289%[19] Operational Highlights - Good product SKUs accounted for 372% of the total in September, a +231 percentage point increase compared to January[7] - GMV from good products reached 447% of total GMV in September[7] - Core market GMV growth for Shanghai, Jiangsu, and Zhejiang was +14% year-over-year[7] - The number of monthly transacting users increased by +41% year-over-year[8] - Average monthly order per user was 46 orders, a +49% year-over-year increase[8] Cash Flow - The company had a RMB 1444 million operating cash inflow[25] - Self-owned fund balance was RMB 303 billion, showing a net increase for the ninth consecutive quarter[25] Strategy - The company is focusing on a high-volume, top-selling product strategy[9] - Expansion into smaller and medium-sized cities in the Jiangsu, Zhejiang, and Shanghai regions is underway, with 17 newly opened stations in Q3[10]

Financial Performance & Growth - Artivion achieved approximately $400 million in revenue and around $70 million in EBITDA for FY24[5] - The company is driving sustained double-digit revenue growth and expects 2x+ EBITDA growth[14] - Full year 2025 revenue guidance is between $439 million and $445 million, representing a year-over-year constant currency growth of 13-14%[73] - Full year 2025 adjusted EBITDA is expected to be between $88 million and $91 million, a year-over-year growth of 24-28%[76] - Net debt leverage is expected to decrease to less than 20x by year-end 2025, with net debt at 18x as of September 30, 2025[69] Business Segments & Market Opportunities - Preservation Services (CryoValve® SG) generated $98 million in revenue in 2024, holding the 1 market position with a 65% share in a $150 million global TAM[17] - Surgical Sealant (BioGlue) had $74 million in revenue in 2024, holding the 2 market position with a 28% share in a $260 million global TAM[17] - On-X aortic valve is uniquely positioned for younger AVR patients, creating a new $100 million U S market opportunity[24] - The company is focused on more complex, less competitive stent graft segments, with a 16% 3-year CAGR[38] - AMDS addresses a $150 million addressable market opportunity and is expected to receive PMA approval by mid-2026[41,46] Clinical Data & Product Performance - On-X aortic heart valve post-approval study (PAS) shows a 66% reduction in major events and an 87% reduction in major bleeding compared to the PROACT IDE study[20] - TRIOMPHE US IDE Trial for Endospan NEXUS® demonstrates a 63% reduction in major adverse event (MAE) rate compared to the reference performance goal[53] - AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control, with 269% MAEs in PERSEVERE vs 580% in the Hemiarch Reference Cohort[47]

Financial Performance & Guidance - Enlight achieved a 46% increase in quarterly revenues and income in 3Q25[10,15] - Adjusted EBITDA grew by 23% in 3Q25 compared to 3Q24[10,15] - The company is raising its 2025 revenue and income guidance to a range of $555-565 million, a 6% increase from the previous forecast[10,16,17] - Adjusted EBITDA guidance for 2025 is raised to $405-415 million, a 4.5% increase[10,16,17] - The company is aiming for an annual revenue and income run rate of approximately $1.5 billion by the end of 2027 and $2 billion by the end of 2028[10] Strategic Expansion & Portfolio Growth - Enlight is expanding its battery storage business with entry into the German and Polish markets[10] - The company acquired 50% of the Bertikow project and 100% of the Edison project to enter the German and Polish energy storage markets[25] - The Bertikow and Edison projects are expected to have a stand-alone storage capacity of 1.1 GWh with an expected first full year EBITDA of $45-49 million and $54-58 million respectively[26] - Enlight's total portfolio has reached 37 FGW (Factored GW), combining generation and storage capacity[44] - The mature portfolio, consisting of operational, under construction, and pre-construction projects, is expected to generate $1.6 billion in revenues and income[48] Capital & Financing - The company raised $4.8 billion in the past 12 months[33] - This includes approximately $1 billion in corporate finance and asset sales, $0.5 billion in tax equity partnerships, and $3.3 billion in project finance for projects in the US & Europe[34] - A $1.4 billion financial close was achieved for the Snowflake A project in Arizona, USA, with a capacity of 600 MW and 1900 MWh[37,38]